Jeppe Ragnar Andersen has a Master of Science degree in Pharmacy, with specialization in endocrinology, from the University of Copenhagen. He also has a Certificate of Leadership from Harvard Business School and a Mini-MBA from AVT Business School. He has been working on clinical trials for Nordic Bioscience since 2007 and has been Head of the Clinical Development Department since 2010. In January 2014 Jeppe was appointed CEO of Nordic Bioscience Clinical Development A/S. Jeppe has managed more than 10 late-stage clinical trials from start to finish and a number of early-stage clinical trials on both scientific and operational levels.
Journal articles
K Henriksen, J R Andersen, B J Riis, N Mehta, R Tavakkol, P Alexandersen, I Byrjalsen, I Valter, B S Nedergaard, C S Teglbjaerg, W Stern, A Sturmer, S Mitta, A J Nino, L A Fitzpatrick, C Christiansen, M A Karsdal (2013) Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Bone 53: 1. 160-166 Mar. |
Authors
P Alexandersen,
J Andersen,
I Byrjalsen,
C Christiansen,
L Fitzpatrick,
K Henriksen,
M Karsdal,
N Mehta,
S Mitta,
B Nedergaard,
A Nino,
B Riis,
W Stern,
A Sturmer,
R Tavakkol,
C Teglbjaerg,
I Valter